Loading
In ASCENT, sacituzumab govitecan beat chemotherapy in tumours with high and medium TROP2 protein, and worked whether or not the patient carried a germline BRCA mutation; the low-TROP2 group was too small to judge.
Prespecified exploratory analysis of ASCENT (metastatic TNBC after two or more chemotherapies) relating tumour Trop-2 expression by validated immunohistochemistry H-score and germline BRCA1/2 status to outcome. Of 468 assessable patients, 290 had Trop-2 data and 292 known BRCA status. Median progression-free survival with sacituzumab versus chemotherapy was 6.9, 5.6 and 2.7 months versus 2.5, 2.2 and 1.6 months for high, medium and low Trop-2; overall survival 14.2, 14.9 and 9.3 versus 6.9, 6.9 and 7.6 months; response 44%, 38% and 22% versus 1%, 11% and 6%. Outcomes favoured sacituzumab with and without germline BRCA1/2 mutation.
TROP2 IHC does not gate sacituzumab govitecan: the label requires no test, and the corpus records TROP2 as an expression readout without a threshold.
Shares Priyanka Sharma, Germline BRCA mutation (gBRCA), BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
Shares Aditya Bardia, ASCENT, Sara M. Tolaney, TROP2.
Shares ASCENT, TROP2, Sacituzumab govitecan, Metastatic triple-negative breast cancer.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Sara M. Tolaney, Immunohistochemistry (IHC), Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Germline BRCA mutation (gBRCA), BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
Shares Priyanka Sharma, Germline BRCA mutation (gBRCA), BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).